<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111047</article-id><article-id pub-id-type="publisher-id">ACM-40021</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_93458392.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  儿童异基因造血干细胞移植后罕见并发症及处理
  Management of Rare Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>丹旗</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姜</surname><given-names>健</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>静</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>立荣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>卢</surname><given-names>愿</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院儿科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>327</fpage><lpage>335</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨异基因造血干细胞移植(allo-genetic hematopoietic stem-cell transplantation, allo-HSCT)后植入功能不良(poor graft function, PGF)和抗利尿激素分泌不当综合征(syndrome of inappropriate antidiuretic hormone secretion, SIADH)的发病机制及治疗措施。分析本例患儿发病的可能原因。方法：报告1例重型再生障碍性贫血(aplastic anemia, AA)患儿allo-HSCT后临床特点及诊治经过。结果：患儿在allo-HSCT回输干细胞后出现II级超急性移植物抗宿主病(graft versus host disease, GVHD)。+17天突发昏迷、惊厥，完善检查示严重低钠血症，尿钠增多，血浆渗透压下降和尿渗透压升高，诊断为SIADH，经限液、补钠等支持治疗后好转。+15天血象未见明显回升，升白、升血小板治疗效果不佳，考虑原发性PGF。随访至移植后3月余仍需成分输血支持，后每月输注间充质干细胞1次(1 &#215; 106/kg∙次，共3次)及血浆置换2次，达AA基本治愈的标准。结论：Allo-HSCT后PGF和SIADH均为严重的、可能导致不良预后的、威胁生命的并发症，其发病机制仍不明确，已知与和移植相关的多种因素相关。为此分析此病例探讨其机制及治疗措施，以改善患者的预后。
    Objective: To investigate the pathogenesis and treatment of poor graft function and syndrome of inappropriate antidiuretic hormone secretion after allogeneic hematopoietic stem cell transplantation, and analyze the possible causes of this case. Methods: The clinical characteristics, diagnosis and treatment of a case of severe aplastic anemia after allo-HSCT are reported. Results: Grade II hyperacute graft versus host disease occurred after allo-HSCT retransfusion of stem cells. 17 days after allo-HSCT after the onset of coma and convulsion, the improved examination showed severe hyponatremia, increased urinary sodium, decreased plasma osmotic pressure and increased urine osmotic pressure. The diagnosis was SIADH, which was improved after supported treatment such as fluid restriction and sodium supplementation. No significant recovery was observed in the blood images for 15 days after allo-HSCT, and the therapeutic effect of white and platelet rising was poor. Primary PGF was considered. The patients were followed up for more than 3 months after transplantation with the support of component blood transfusion. After that, the patients were injected with mesenchymal stem cells once a month (1 &#215; 106/kg∙time, a total of 3 times) and plasmapheresis two times, reaching the standard of AA basic cure. Conclusions: Both PGF and SIADH after allo-HSCT are severe, potentially life-threatening complications with poor prognosis. Their pathogenesis is still unclear and is known to be associated with multiple factors associated with transplantation. Therefore, this case was analyzed to explore its mechanism and treatment measures to improve the prognosis of the patient. 
  
 
</p></abstract><kwd-group><kwd>再生障碍性贫血，异基因造血干细胞移植，单倍体移植，植入功能不良，低钠血症，抗利尿激素分泌不当综合征, Aplastic Anemia</kwd><kwd> Allo-Genetic Hematopoietic Stem-Cell Transplantation</kwd><kwd> Haploid Transplantation</kwd><kwd> Poor Graft Function</kwd><kwd> Hyponatremia</kwd><kwd> Syndrome of Inappropriate Antidiuretic Hormone Secretion</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨异基因造血干细胞移植(allo-genetic hematopoietic stem-cell transplantation, allo-HSCT)后植入功能不良(poor graft function, PGF)和抗利尿激素分泌不当综合征(syndrome of inappropriate antidiuretic hormone secretion, SIADH)的发病机制及治疗措施。分析本例患儿发病的可能原因。方法：报告1例重型再生障碍性贫血(aplastic anemia, AA)患儿allo-HSCT后临床特点及诊治经过。结果：患儿在allo-HSCT回输干细胞后出现II级超急性移植物抗宿主病(graft versus host disease, GVHD)。+17天突发昏迷、惊厥，完善检查示严重低钠血症，尿钠增多，血浆渗透压下降和尿渗透压升高，诊断为SIADH，经限液、补钠等支持治疗后好转。+15天血象未见明显回升，升白、升血小板治疗效果不佳，考虑原发性PGF。随访至移植后3月余仍需成分输血支持，后每月输注间充质干细胞1次(1 &#215; 10<sup>6</sup>/kg∙次，共3次)及血浆置换2次，达AA基本治愈的标准。结论：Allo-HSCT后PGF和SIADH均为严重的、可能导致不良预后的、威胁生命的并发症，其发病机制仍不明确，已知与和移植相关的多种因素相关。为此分析此病例探讨其机制及治疗措施，以改善患者的预后。</p></sec><sec id="s2"><title>关键词</title><p>再生障碍性贫血，异基因造血干细胞移植，单倍体移植，植入功能不良，低钠血症，抗利尿激素分泌不当综合征</p></sec><sec id="s3"><title>Management of Rare Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children</title><p>Danqi Wang, Jian Jiang, Jing Yang, Lirong Sun, Yuan Lu<sup>*</sup></p><p>Pediatrics Department of Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/47-1571873x5_hanspub.png" /></p><p>Received: Dec. 25<sup>th</sup>, 2020; accepted: Jan. 19<sup>th</sup>, 2021; published: Jan. 27<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/47-1571873x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the pathogenesis and treatment of poor graft function and syndrome of inappropriate antidiuretic hormone secretion after allogeneic hematopoietic stem cell transplantation, and analyze the possible causes of this case. Methods: The clinical characteristics, diagnosis and treatment of a case of severe aplastic anemia after allo-HSCT are reported. Results: Grade II hyperacute graft versus host disease occurred after allo-HSCT retransfusion of stem cells. 17 days after allo-HSCT after the onset of coma and convulsion, the improved examination showed severe hyponatremia, increased urinary sodium, decreased plasma osmotic pressure and increased urine osmotic pressure. The diagnosis was SIADH, which was improved after supported treatment such as fluid restriction and sodium supplementation. No significant recovery was observed in the blood images for 15 days after allo-HSCT, and the therapeutic effect of white and platelet rising was poor. Primary PGF was considered. The patients were followed up for more than 3 months after transplantation with the support of component blood transfusion. After that, the patients were injected with mesenchymal stem cells once a month (1 &#215; 10<sup>6</sup>/kg∙time, a total of 3 times) and plasmapheresis two times, reaching the standard of AA basic cure. Conclusions: Both PGF and SIADH after allo-HSCT are severe, potentially life-threatening complications with poor prognosis. Their pathogenesis is still unclear and is known to be associated with multiple factors associated with transplantation. Therefore, this case was analyzed to explore its mechanism and treatment measures to improve the prognosis of the patient.</p><p>Keywords:Aplastic Anemia, Allo-Genetic Hematopoietic Stem-Cell Transplantation, Haploid Transplantation, Poor Graft Function, Hyponatremia, Syndrome of Inappropriate Antidiuretic Hormone Secretion</p><disp-formula id="hanspub.40021-formula32"><graphic xlink:href="//html.hanspub.org/file/47-1571873x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/47-1571873x8_hanspub.png" /> <img src="//html.hanspub.org/file/47-1571873x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>异基因造血干细胞移植(allo-HSCT)目前被广泛应用于良、恶性血液病的治疗，并取得了令人满意的疗效。近年来在包括重症联合免疫缺陷综合征等免疫缺陷病、黏多糖累积症等遗传代谢病在内的其他先天疾病的应用也越来越广泛。再生障碍性贫血(AA)首选HLA相合同胞供者异基因造血干细胞移植，部分免疫抑制治疗无效的年轻患者也可尝试非血缘或单倍型allo-HSCT [<xref ref-type="bibr" rid="hanspub.40021-ref1">1</xref>]。植入功能不良(PGF)、抗利尿激素分泌不当综合征(SIADH)均为allo-HSCT后严重的并发症，常伴出血、感染，甚至危及生命，严重影响患者移植预后。现报道我中心诊治的1例急性再生障碍性贫血(aplastic anemia, AA) allo-HSCT后同时合并PGF及SIADH，复习相关文献，并探讨本例患儿发病机制及治疗策略。</p></sec><sec id="s6"><title>2. 病例资料</title><p>患儿男，3岁，因“鼻衄伴血象异常3天，发热伴咳嗽1天。”入院。门诊已予抗感染及成分输血等支持治疗。入院时查体：神志清，精神尚可，重度贫血貌，皮肤黏膜苍白，未见出血点。咽红，呼吸平稳，双肺呼吸音略粗，双肺未闻及明显干湿啰音。心音有力，心律齐，各瓣膜听诊区未闻及杂音。腹软，无压痛、反跳痛，肠鸣音存在，肝、脾肋下未触及。双下肢无浮肿。神经系统查体未见异常。实验室检查：血常规 + CRP：白细胞计数6.71 &#215; 10<sup>9</sup>/L，中性粒细胞计数2.04 &#215; 10<sup>9</sup>/L，血红蛋白57 g/L，血小板1 &#215; 10<sup>9</sup>/L，网织红细胞计数0.003 &#215; 10<sup>12</sup>/L，网织红细胞百分率0.16%，C-反应蛋白2.85 mg/L；尿隐血2+，免疫球蛋白IgE 133.40 IU/mL，抗Ro-52抗体阳性(+)，抗SSA抗体阳性(+)，生化检查未见明显异常。EB病毒及巨细胞病毒DNA均小于5.00E+03。胸部CT示右肺大片状高密度，符合炎性改变，颅脑CT示腺样体增生可能，上下腹、盆腔CT未见异常。骨髓细胞学检查示骨髓增生活跃，粒红比为0.5:1，粒系、红系增生减低，淋巴细胞比例增高，约占82%，网状细胞比例明显增高，非造血细胞团多见。未见巨核细胞，血小板少见。骨髓活检示骨髓细胞容积30%，可见少量粒红系细胞，内见少量嗜酸性粒细胞，未见巨核细胞，可见部分淋巴细胞、浆细胞，比例增高。SCGE检测示外周血淋巴细胞无明显DNA损伤，SCGE检测结果为阴性；骨髓染色体核型分析未见分裂相；MDS免疫分型及PNH检查未见明显异常；MMC染色体畸变检测示未见染色体撕裂，MMC检测结果为阴性；范可尼贫血基因突变检测示BRIP1基因p.A144T错义突变。诊断为急性再生障碍性贫血(acute aplastic anemia, AAA)。予抗感染、成分输血，及口服环孢素(6.5 mg/kg∙d)、达那唑、参芪十一味颗粒、复方皂矾丸、赖氨肌醇维生素B12等治疗。而后6个月时间内患儿反复发热、反复输血：约1周输注一次红细胞及血小板，不能脱离输血，故符合造血干细胞移植指征。此患儿有一弟弟，为完全不合。同时中华骨髓库及脐血库中均未找到合适供者，故采用父供子(A+供O+)半相合移植。</p><p>患儿于2018-10-03进行移植前预处理，预处理方案为Bu + Cy/ATG方案：Bu 0.8 mg/kg ivgtt q6h (−7~−6天)；CTX 50 mg/kg ivgtt qd (−5~−2天)；ATG 25 mg qd (−5~−4天)，50 mg qd (−3~−2天)；CTX用药期间，大量水化、碱化(总液体量2500 ml/m<sup>2</sup>/d)。辅以预防急性移植物抗宿主反应：环孢素(1.25 mg/kg/次，ivgtt，bid，−7天起) + MTX (15 mg/m<sup>2</sup>，+1天；10 mg/m<sup>2</sup>，+3，+5，+11天) + MMF (0.25 g，po，bid，−7天起)。</p><p>预处理后回输其父骨髓血360 ml，其中单个核细胞0.96 &#215; 10<sup>8</sup>/kg，CD34+细胞计数0.27 &#215; 10<sup>8</sup>/kg。回输过程中，患儿出现血红蛋白尿，因为父供子(A+供O+)主不合，考虑出现溶血反应，立即予应用甲强龙及水化、碱化后缓解，两次血红蛋白尿后尿量转清亮。第二天输注父外周血干细胞，共回输外周血57 ml，其中单个核细胞计数43.9 &#215; 10<sup>8</sup>/kg。+10天患儿出现发热，最高39.5℃，水样便约2~4次/天，总量 &lt; 200 ml/天，伴背部及四肢皮疹，考虑急性II级GVHD，予甲强龙(1 mg/kg∙d)、抗感染及对症支持处理。+15天血常规示中性粒细胞0.06 &#215; 10<sup>9</sup>/L，血红蛋白69 g/L，血小板4 &#215; 10<sup>9</sup>/L，未见明显上升，考虑可能存在原发性植入功能不良(poor graft function, PGF)，加大甲强龙剂量至2 mg/kg∙d，同时予升白、升血小板及对症输血支持处理。同时送检外周血STR为100%，呈完全嵌合状态。+17天患儿突然出现抽搐发作，表现为：口吐白沫，意识不清，四肢抽动，呼之不应，查体：体温37℃，心率加快(110~130次/分)，血压升高(最高140/90 mmHg)，双侧瞳孔对光反射迟钝，右侧球结膜出血，全身皮肤散在皮疹，四肢肌张力增高，右下肢巴氏征阴性。立即予吸氧、鲁米那止惊，甘露醇20 g降颅压。血常规结果回示血小板27 &#215; 10<sup>9</sup>/L，血钠111.70 mmol/L，不排除脑出血可能，立即予巴曲亭、止血敏及维生素K1、输注血小板处理，暂停环孢素，3张含钠液200 ml/d持续泵入，后患儿出现心率加快(160~170次/分)，呼吸35~40次/分，血压120/70 mmHg，考虑心衰，予西地兰强心，呋塞米利尿，持续泵入硝普钠降压处理。期间患儿仍反复抽搐发作2~3次后停止，未再发作，且血钠最高约118 mmol/L，行卧位醛固酮472.50 pg/ml，血管紧张素II79.50 ng/ml，血渗透压226.19 mOSM/L，尿渗透压389 mOSM/L，24小时尿钠2.78 g/24h (120.71 mmol/24h)，血钾4.03 mmol/L，血氯88.9 mmol/L，尿素氮2.42 mmol/L，肌酐12.00 μmol/L，尿酸13.00 μmol/L，血糖10.28 mmol/L，环孢素血药浓度58.90 μg/L，甲功正常。头颅MRI示双侧枕叶少许异常信号影，不除外脱髓鞘改变。结合以上检查结果，可以排除脑出血，诊断为抗利尿激素分泌不当综合征(syndrome of inappropriate antidiuretic hormone secretion, SIADH)，立即予限液80 ml/kg∙d，持续泵入硝普钠控压，持续泵入3~5张含钠液，及成分输血等治疗。+29天血钠回升至130.50 mmol/L，每日口服6支浓钠(10 ml: 1 g)，并逐渐减少静脉补钠量；中性粒细胞达1.0 &#215; 10<sup>9</sup>/L以上，达到粒细胞重建标准 [<xref ref-type="bibr" rid="hanspub.40021-ref2">2</xref>]，但血红蛋白波动于50~70 g/L，血小板波动于10 &#215; 10<sup>9</sup>/L左右，输血后可上升，考虑存在PGF，应用甲强龙、G-CSF、TPO后稍好转，输血间隔时间较移植前延长，约2周输注一次红细胞，约1周输注一次血小板，但仍无法脱离输血。+32天复查骨髓示骨髓增生低下，行骨髓的嵌合率为100%，呈完全供者嵌合。+50天停止静脉补充高张含钠液，每日仍口服6支浓钠(10 ml: 1 g)，动态监测血钠维持在130 mmol/L以上(见图1)。移植后血红蛋白及血小板变化趋势见图2。</p><p>期间动态监测铁蛋白，+45 d铁蛋白最高达5712 μg/L，予去铁胺治疗，+56天下降至3624 μg/L。移植后3月余，输注间充质干细胞，细胞计数1 &#215; 10<sup>6</sup>/kg∙次，每月输注一次，共3次，于间隔期行血浆置换，同时服用艾曲波帕。目前贫血和出血症状消失，白细胞达4 &#215; 10<sup>9</sup>/L，血红蛋白达100 g/L，血小板达100 &#215; 10<sup>9</sup>/L，达到AA基本治愈的标准。</p><p>图1. 移植后血钠水平变化</p><p>图2. 移植后血红蛋白及血小板变化</p></sec><sec id="s7"><title>3. 讨论</title><sec id="s7_1"><title>3.1. 植入功能不良</title><p>Allo-HSCT是治疗良、恶性血液病的有效方法，目前被广泛应用于临床，但是也存在一些长期的问题。移植失败是allo-HSCT威胁生命的并发症，包括移植排斥和PGF，两者可以通过检查嵌合率来鉴别 [<xref ref-type="bibr" rid="hanspub.40021-ref3">3</xref>]。移植排斥是混合嵌合或全受者嵌合 [<xref ref-type="bibr" rid="hanspub.40021-ref4">4</xref>]。Allo-HSCT后部分患者造血虽已转变为供者来源，但造血恢复延迟或恢复不完全，即为移植物植入功能不良(PGF) [<xref ref-type="bibr" rid="hanspub.40021-ref5">5</xref>]，即在完全供者型嵌合状态下，供者细胞未能在受者体内重建适宜的造血、免疫功能。根据最新的文献，PGF是指移植后至少存在两系细胞减少，包括持续的血小板 ≤ 20 &#215; 10<sup>9</sup>/L，血红蛋白 ≤ 70 g/L，和/或中性粒细胞 ≤ 0.5 &#215; 10<sup>9</sup>/L，骨髓检查示骨髓增生低下，呈完全嵌合状态，不伴有严重的GVHD或疾病复发 [<xref ref-type="bibr" rid="hanspub.40021-ref6">6</xref>]。PGF分为原发性和继发性。原发性PGF是指患者直到超过allo-HSCT后28天，血常规一直未达到造血重建标准；继发性PGF是指移植后已获得造血重建的患者再次出现两系或三系血细胞减少，骨髓增生减低、骨髓呈供者完全嵌合状态 [<xref ref-type="bibr" rid="hanspub.40021-ref5">5</xref>]。</p><p>近十年来，随着单倍体移植(Haplo-HSCT)临床应用的增加，PGF成为allo-HSCT术后高发病率和高死亡率的一个严重的障碍 [<xref ref-type="bibr" rid="hanspub.40021-ref3">3</xref>]。之前的研究显示，恶性血液病移植后PGF的发生率在5%~27%之间 [<xref ref-type="bibr" rid="hanspub.40021-ref6">6</xref>]。重型再生障碍性贫血患者allo-HSCT后PGF的发病率则为14.4% [<xref ref-type="bibr" rid="hanspub.40021-ref1">1</xref>]。由于感染和出血，PGF死亡率很高，尤其是原发性PGF [<xref ref-type="bibr" rid="hanspub.40021-ref4">4</xref>]。Zhao [<xref ref-type="bibr" rid="hanspub.40021-ref4">4</xref>] 等进行的一项830例allo-HSCT后血液病的患者的病例对照研究显示，与GGF组相比，原发性PGF患者的1年生存率明显较低(25.0% VS 90.6%)。但是目前PGF的发病机制尚不明确。更好的了解PGF的发病机制可以指导临床有效的治疗，并且提高allo-HSCT患者的预后。</p><p>Zhao [<xref ref-type="bibr" rid="hanspub.40021-ref4">4</xref>] 等的研究显示，CD34+细胞剂量 &lt; 5 &#215; 10<sup>6</sup>/kg、血清铁蛋白(SF) &gt; 2000 ng/ml以及巨脾是原发性PGF的3个独立危险因素。此前有研究显示，CD34+细胞剂量 &gt; 3.25 &#215; 10<sup>6</sup>/kg与中性粒细胞数提高有关 [<xref ref-type="bibr" rid="hanspub.40021-ref7">7</xref>]，但多变量分析没有发现一个明确的截断值与造血恢复有关。当CD34+细胞剂量 &lt; 8 &#215; 10<sup>6</sup>/kg，造血恢复明显延迟 [<xref ref-type="bibr" rid="hanspub.40021-ref3">3</xref>]。铁蛋白是评估铁过载的一个重要的指标。铁过载会增加细胞内活性氧(ROS)的含量，ROS水平增高会促进DNA的损伤和细胞凋亡，导致CD34+细胞的衰竭 [<xref ref-type="bibr" rid="hanspub.40021-ref4">4</xref>]。巨脾的患者移植成活率较低可能有两方面的原因，一是关注的CD34+细胞可能被脾脏隔离，导致归巢时间延迟和骨髓细胞减少，二是新生成的细胞被脾脏破坏 [<xref ref-type="bibr" rid="hanspub.40021-ref4">4</xref>]。因此，CD34+细胞剂量较低，SF水平较高，以及巨脾的移植受者，移植后应密切监测移植后PGF的发展。</p><p>Xiao [<xref ref-type="bibr" rid="hanspub.40021-ref8">8</xref>] 等进行了一项124名allo-HSCT后的患者的回顾性研究，单变量分析结果显示，年龄、供受者血型及巨细胞病毒(CMV)感染(30天内)是PGF的潜在危险因素，而多变量分析结果表明，这三者是重大的危险因素。此研究将124名患儿按年龄 &lt; 20岁、20~30岁、30~40岁、&gt;40岁分为亚组，结果显示，随着年龄的增长，PGF的风险增加了2.747倍。</p><p>供受者ABO血型分析结果表明，ABO血型主侧不合比主次均不合发生PGF的危险程度更高。有文献表明，血型不匹配的受体更可能发生免疫介导的溶血和延迟的红细胞移植 [<xref ref-type="bibr" rid="hanspub.40021-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref10">10</xref>]。CMV是一种人类疱疹病毒，大多数情况下呈潜伏感染状态，但是HSCT之后的患者免疫功能下降，更容易受CMV感染，导致多器官CMV病发生 [<xref ref-type="bibr" rid="hanspub.40021-ref8">8</xref>]。CMV可感染骨髓直接抑制造血，也可感染骨髓基质细胞间接抑制造血 [<xref ref-type="bibr" rid="hanspub.40021-ref11">11</xref>]。</p><p>此外，有文献显示，骨髓造血微环境在PGF的发生中起着重要的作用，骨髓微环境中免疫异常、内皮细胞损伤、间充质干细胞(MSCs)损伤以及ROS增多引起的干细胞损伤均与PGF的发生相关 [<xref ref-type="bibr" rid="hanspub.40021-ref5">5</xref>]。最近的研究显示，与GGF组相比，PGF的患者MSCs更少且功能失调，造血支持能力显著下降 [<xref ref-type="bibr" rid="hanspub.40021-ref12">12</xref>]。</p><p>本例患儿发生PGF的原因可能为：① 血清铁蛋白高：因移植前反复输血，移植前测血清铁蛋白最高2314 ng/ml (&gt;2000 ng/ml)，ROS水平增加，导致CD34+细胞衰竭；② 供受者血型不合：移植类型为父供子，HLA半相合，A+供O+，为单倍体移植、ABO血型主侧不合，易发生GVHD和延迟植入；③骨髓微环境异常，造血支持能力下降。</p><p>CD34+细胞输注是治疗PGF的常用方法。Mainardi [<xref ref-type="bibr" rid="hanspub.40021-ref7">7</xref>] 等采用CD34+细胞输注治疗50例儿童PGF患者，8周内78.8%患者一系或两系细胞恢复，36.5%患者获得完全的血液学反应。I~III度aGVHD发生率为6%且能被完全治愈，无Ⅳ度GVHD发生。可见输注分选的CD34+细胞是治疗儿童PGF安全、有效的方法 [<xref ref-type="bibr" rid="hanspub.40021-ref5">5</xref>]。Mohty R [<xref ref-type="bibr" rid="hanspub.40021-ref13">13</xref>] 等对10名allo-HSCT后合并PGF的患者进行CD34+细胞“Boost”治疗的研究，输注的CD34+细胞中位数为4.77 &#215; 10<sup>6</sup>/kg，结果7名患者获得了造血重建，3名患者出现了持续性的贫血和/或血小板减少，并最终死于感染。研究分析，混合供体嵌合和细胞减少的患者处于移植物衰竭状态，不能从“Boost”治疗中获益，而应采用第二次allo-HSCT治疗。</p><p>一项研究显示，20名PGF (包括7名原发性PGF)患者，以1 &#215; 10<sup>6</sup>/kg MSC为单次剂量，间隔28天输注一次，输注1~3次，17名患者获得了造血恢复(其中包括5名原发性PGF)，17名患者部分恢复造血和完全恢复造血的中位时间分别为24天和42天 [<xref ref-type="bibr" rid="hanspub.40021-ref4">4</xref>]。国内的一项研究 [<xref ref-type="bibr" rid="hanspub.40021-ref14">14</xref>]，10例allo-HSCT后发生PGF的患者，以1 &#215; 10<sup>6</sup>/kg MSC为单次剂量，3名患者接受1次、7名患者接受2次MSC治疗，所有患者均实现了造血恢复，5名患者在MSC治疗后出现了EB病毒的再激活。由此可见，输注MSC是治疗PGF的有效方法，但是MSC是否会增加EBV感染及EBV相关性PTLD (post-transplant lymphoproliferative disease，移植后淋巴细胞增殖性疾病)的发生有待于进一步研究 [<xref ref-type="bibr" rid="hanspub.40021-ref5">5</xref>]。此外，其他文献表明，二次allo-HSCT、铁鳌合治疗、ROS清除剂N-乙酰-L-半胱氨酸等 [<xref ref-type="bibr" rid="hanspub.40021-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref15">15</xref>] 能有效的预防或者治疗PGF。</p></sec><sec id="s7_2"><title>3.2. 低钠血症和抗利尿激素分泌不当综合征</title><p>低钠血症(hyponatremia) [<xref ref-type="bibr" rid="hanspub.40021-ref2">2</xref>] 是指血浆钠浓度低于136 mmol/L，是常见的电解质紊乱。根据血浆渗透压与低钠血症的关系，低钠血症分为高渗性、低渗性和等渗性低钠血症。其中低渗性低钠血症根据容量状态分为3组：低容量性、高容量性、正常容量性低钠血症。SIADH指体内抗利尿激素(AVP或ADH)分泌异常增多或其活性作用超常，并不受血容量和血浆渗透压制约，出现以细胞内水潴留、稀释性低钠血症、尿排钠增多为特征的临床综合征，是临床上最常见的一种等容量性低渗性低钠血症，约占低钠血症的60%。Allo-HSCT后严重的低钠血症和SIADH，是罕见但威胁生命的并发症 [<xref ref-type="bibr" rid="hanspub.40021-ref16">16</xref>]。</p><p>SIADH的诊断主要依靠临床表现和实验室检查，需要除外其他引起低钠血症的原因，如高血糖、酒精或甘油三酯引起的假性低钠状态等。一旦怀疑SIADH，就应尽快检查血糖、血脂、皮质醇、甲功、肝肾功及血浆渗透压、尿渗透压、尿钠、尿钾等 [<xref ref-type="bibr" rid="hanspub.40021-ref17">17</xref>]。以下实验室检查对诊断有价值 [<xref ref-type="bibr" rid="hanspub.40021-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref17">17</xref>]：① 低钠血症、血浆渗透压 ≤ 270 mOsm/L；② 尿钠增加(常 &gt; 30 mmol/d)。尿渗透压 &gt; 100 mOsm/L；③ 低尿酸血症。</p><p>本例患儿移植后第17天出现惊厥时血钠111.70 mmol/L (最低103.20 mmol/L)，血浆渗透压226.19 mOsm/L，尿渗透压389 mOsm/L，24小时尿钠2.78 g/24h (120.71 mmol/24h)，血尿酸13.00 μmol/L，余生化指标均未见明显异常。颅脑影像学检查排除颅内病变，血凝检查未见凝血异常。外周血涂片未见破碎红细胞等。故考虑SIADH诊断。</p><p>国内已有不少allo-HSCT后SIADH个案报道 [<xref ref-type="bibr" rid="hanspub.40021-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref21">21</xref>]，但儿童病例相对较少。Kobayashi等报告了HSCT后SIADH的发病率以及相关因素的研究，140例HSCT治疗后的患儿的研究示40%患儿出现了低钠血症，中位时间为移植后19 d (0~74 d)，其中SIADH占11.4% [<xref ref-type="bibr" rid="hanspub.40021-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref20">20</xref>]。</p><p>根据allo-HSCT后SIADH发生的时间，可分为早期(&lt;100 d)和晚期(&gt;100 d)。SIADH的病因很多，但allo-HSCT后SIADH的发病机制目前尚未明确。有文献报道 [<xref ref-type="bibr" rid="hanspub.40021-ref16">16</xref>]，早期SIADH的危险因素包括替代供者、HLA错配，移植类型如脐血干细胞移植，预处理方案包括白消安和大剂量环磷酰胺(CTX)，甲氨蝶呤(MTX)预防GVHD等。还包括抗肿瘤药物，如长春新碱、异环磷酰胺、他克莫司、塞替派和伊马替尼。GVHD可刺激ADH的释放，SIADH在allo-HSCT后急性GVHD的发展，特别是非亲缘供者或HLA错配的移植情况下，提示免疫机制和GVHD触发的炎症反应可能是SIADH的潜在原因。此外，很多研究报告显示allo-HSCT后水痘–带状疱疹(VZV)的全身性感染会引起SIADH [<xref ref-type="bibr" rid="hanspub.40021-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref20">20</xref>]。1993年Dakos等报道1例慢粒allo-HSCT后5个月出现皮肤带状疱疹前出现了SIADH [<xref ref-type="bibr" rid="hanspub.40021-ref18">18</xref>]。Rau等发现了剧烈腹痛、SIADH和广泛VZV感染的三联征，出现在移植后皮肤症状出现之前 [<xref ref-type="bibr" rid="hanspub.40021-ref22">22</xref>]。</p><p>本例患儿发病的原因可能为多因素的：① 患儿进行了HLA半相合移植，并发超急性GVHD，炎症因子水平增高，ADH释放增加，诱发SIADH；② 预处理时白消安、大剂量CTX及免疫抑制剂等药物因素。</p><p>急性(即48小时内发病)和重度低钠血症(血钠 ≤ 120 mol/L)的患者通常有症状，需要密切监护，因为合并神经系统疾病的风险很高，在这种情况下，需要尽快干预纠正 [<xref ref-type="bibr" rid="hanspub.40021-ref23">23</xref>]。</p><p>目前的治疗措施液体限制、补钠及药物治疗。液体限制是治疗SIADH的基石，限制入液量500~1200 ml/d [<xref ref-type="bibr" rid="hanspub.40021-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref23">23</xref>]，推荐800~1000 ml/d。补钠治疗，建议补充高渗盐溶液(3% NaCl溶液) [<xref ref-type="bibr" rid="hanspub.40021-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref23">23</xref>]。为避免血钠的进一步下降，所给液体的渗透压必须高于尿的渗透压 [<xref ref-type="bibr" rid="hanspub.40021-ref23">23</xref>]。有文献 [<xref ref-type="bibr" rid="hanspub.40021-ref17">17</xref>] 建议首先静滴150 ml 3%盐溶液，静滴15分钟，若无明显临床改善，20分钟后可重复一次。关键是控制补钠的速度，血钠的过快升高会导致严重的神经损害，很多病例显示，血钠每天增加&gt;12 mmol/L会导致脑桥髓鞘溶解症 [<xref ref-type="bibr" rid="hanspub.40021-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref23">23</xref>]，有遗留神经系统后遗症的风险。多个报道及研究表明 [<xref ref-type="bibr" rid="hanspub.40021-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref23">23</xref>]，安全的补钠速度为第一个6小时上升不超过6 mmol/L，24小时上升不超过10 mmol/L，48小时上升不超过18 mmol/L。老年人、16岁以下的儿童、营养不良、酗酒、中枢神经系统疾病、低氧血症，以及术后，都是发生脱髓鞘的危险因素，安全的补钠原则是24小时上升不超过8 mmol/L，48小时不超过14 mmol/L [<xref ref-type="bibr" rid="hanspub.40021-ref17">17</xref>]。在高渗液补充期间，必须密切监测患者，至少间隔4小时检查一次血钠，间隔2小时则更佳。当患者的症状消失，和/或达到了一个安全的血钠水平(≥120 mmol/L)，和/或整个纠正量达到了18 mmol/L，就要停止高渗盐溶液的灌注 [<xref ref-type="bibr" rid="hanspub.40021-ref23">23</xref>]。如果患者因为各种原因不能严格限液，或24~48小时后患者对限液反应不佳，则需考虑二线药物治疗 [<xref ref-type="bibr" rid="hanspub.40021-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.40021-ref25">25</xref>]：① ADH受体拮抗剂：作用机制为通过与肾脏集合管上V2受体竞争性结合，抑制肾小管对水的重吸收，达到排水利尿的作用。目前主要有考尼伐坦和托伐普坦两种类型。② 利尿剂：袢利尿剂可抑制肾小管袢升支对钠的重吸收，阻碍肾髓质高渗状态的形成，进而阻止肾小管内水的重吸收，起到抑制ADH并促进排水的作用。应用呋塞米可快速纠正SIADH引起的低钠血症。③ 尿素：尿素为溶质性利尿剂。通过促进多余水分排泄以及减少尿钠排除起到升高血钠水平的目的。遗憾的是，以上治疗措施的提出多数是以成人SIADH为研究背景的，而儿童SIADH还需要进一步探索。</p><p>本例患儿经有效限液、补钠及支持治疗后，血钠维持在130 mmol/L左右，临床及影像学检查均未发现明显的神经系统后遗症。截止至发稿日，患儿三系细胞及血钠水平稳定，未再出现神经系统症状。</p></sec></sec><sec id="s8"><title>4. 结论</title><p>总而言之，PGF和SIADH均为allo-HSCT后严重的、可能导致不良预后的、威胁生命的并发症，其发病机制仍不明确，已知与和移植相关的多种因素相关。临床医生应提高对二者的认识。尽管已有多种预防及治疗措施应用于临床，但是还需要进一步探索其发生、发展及有效的预防、治疗措施，改善患者的预后。</p></sec><sec id="s9"><title>文章引用</title><p>王丹旗,姜 健,杨 静,孙立荣,卢 愿. 儿童异基因造血干细胞移植后罕见并发症及处理Management of Rare Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children[J]. 临床医学进展, 2021, 11(01): 327-335. https://doi.org/10.12677/ACM.2021.111047</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40021-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">师辰燕, Mamal, A., 刘增慧, 吴晓雄, 夏凌辉, 聂大年, 赖永榕, 等. 重型再生障碍性贫血行异基因造血干细胞移植后植入功能不良的危险因素分析[J]. 中华血液学杂志, 38(9): 761-766.  
https://doi.org/10.3760/cma.j.issn.0253-2727.2017.09.006</mixed-citation></ref><ref id="hanspub.40021-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">林果为, 王吉耀, 葛均波. 实用内科学[M]. 第15版. 北京: 人民卫生出版社, 2017: 2.</mixed-citation></ref><ref id="hanspub.40021-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Yuan, K. (2019) Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation—An Old Complication with New Insights. Seminars in Hematology, 56, 215-220. https://doi.org/10.1053/j.seminhematol.2018.08.004</mixed-citation></ref><ref id="hanspub.40021-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, Y.M., Gao, F., Shi, J.M., Luo, Y., Tan, Y.M., Lai, X.Y., et al. (2019) Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 25, 1898-1907. https://doi.org/10.1016/j.bbmt.2019.05.036</mixed-citation></ref><ref id="hanspub.40021-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">韩明哲. 异基因造血干细胞移植后植入功能不良研究进展[J]. 临床血液学杂志, 2019, 32(9): 660-664. 
http://dx.chinadoi.cn/10.13201/j.issn.1004-2806.2019.09.003</mixed-citation></ref><ref id="hanspub.40021-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Sun, Y.Q., He, G.L., Chang, Y.J., Xu, L.-P., Zhang, X.-H., Han, W., et al. (2015) The Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function after Unmanipulated Haploidentical Stem Cell Transplantation. Annals of Hematology, 94, 1699-705. https://doi.org/10.1007/s00277-015-2440-x</mixed-citation></ref><ref id="hanspub.40021-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Mainardi, C., Ebinger, M., Enkel, S., Feuchtinger, T., Teltschik, H.-M., Eyrich, M., et al. (2018) CD34+ Selected Stem Cell Boosts Can Improve Poor Graft Function after Paediatric Allogeneic Stem Cell Transplantation. British Journal of Haematology, 180, 90-99. https://doi.org/10.1111/bjh.15012</mixed-citation></ref><ref id="hanspub.40021-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Xiao, Y., Song, J.Y., Jiang, Z.J., Li, Y.H., Gao, Y., Xu, W.N., et al. (2014) Risk-Factor Analysis of Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. International Journal of Medical Sciences, 11, 652-657. https://doi.org/10.7150/ijms.6337</mixed-citation></ref><ref id="hanspub.40021-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Rowley, S.D., Liang, P.S. and Ulz, L. (2000) Transplantation of ABO-Incompatible Bone Marrow and Peripheral Blood Stem Cell Components. Bone Marrow Transplant, 26, 749-757. https://doi.org/10.1038/sj.bmt.1702572</mixed-citation></ref><ref id="hanspub.40021-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Benjamin, R.J., Connors, J.M., McGurk, S., Hallowell Churchill, W. and Antin, J.H (1998) Prolonged Erythroid Aplasia after Major ABO-Mismatched Transplantation for Chronic Myelogenous Leukemia. Biol Blood Marrow Transplant, 4, 151-156. https://doi.org/10.1053/bbmt.1998.v4.pm9923413</mixed-citation></ref><ref id="hanspub.40021-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Torok-Storb, B., Boeckh, M., Hoy, C., Leisenring, W., Myerson, D. and Gooley, T. (1997) Association of Specific Cytomegalovirus Genotypes with Death from Myelosuppression after Marrow Transplantation. Blood, 90, 2097-102.</mixed-citation></ref><ref id="hanspub.40021-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Song, Y., Zhao, H.Y., Lyu, Z.S., Cao, X.-N., Shi, M.-M., Wen, Q., et al. (2018) Dysfunctional Bone Marrow Mesenchymal Stem Cells in Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 24, 1981-1989. https://doi.org/10.1016/j.bbmt.2018.06.021</mixed-citation></ref><ref id="hanspub.40021-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Mohty, R., Brissot, E., Battipaglia, G., Ruggeri, A., Sestili, S., Mediavilla, C., et al. (2019) CD34+-Selected Stem Cell “Boost” for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Current Research in Translational Medicine, 67, 112-114. https://doi.org/10.1016/j.retram.2018.12.003</mixed-citation></ref><ref id="hanspub.40021-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">刘晓丹, 范志平, 彭延文, 黄芬, 江千里, 张贤, 等. 第三方骨髓间充质干细胞治疗异基因造血干细胞移植后植入功能不良[J]. 中华血液学杂志, 2011, 33(2): 98-102.  
http://dx.chinadoi.cn/10.3760/cma.j.issn.0253-2727.2012.02.007</mixed-citation></ref><ref id="hanspub.40021-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Olivieri, J., Mancini, G., Goteri, G., Scortechini, I., Giantomassi, F., Chiarucci, M. (2016) Reversal of Poor Graft Function with Iron-Chelating Therapy after Allogeneic Transplantation for Severe Aplastic Anemia. Leukemia &amp; Lymphoma, 57, 965-968. https://doi.org/10.3109/10428194.2015.1085530</mixed-citation></ref><ref id="hanspub.40021-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wei, J., Xiao, Y., Yu, X., Zhou, J. and Zhang, Y. (2010) Early Onset of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) after Allogeneic Haematopoietic Stem Cell Transplantation: Case Report and Review of the Literature. Journal of International Medical Research, 38, 705-710. https://doi.org/10.1177/147323001003800235</mixed-citation></ref><ref id="hanspub.40021-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Paul, G., John, A., Pierre-Marc, B., Cohen, M., Cranston, I., Murray, R.D., et al. (2015) The Diagnosis and Management of Inpatient Hyponatraemia and SIADH. European Journal of Clinical Investigation, 45, 888-894.  
https://doi.org/10.1111/eci.12465</mixed-citation></ref><ref id="hanspub.40021-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">江倩, 刘开彦, 黄晓军, 卢纹凯. 异基因造血干细胞移植后的抗利尿激素分泌失调综合征一例报告——附文献复习[J]. 中华血液学杂志, 2006(2): 78-81.</mixed-citation></ref><ref id="hanspub.40021-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">邹德慧, 王东浩, 王迎, 赵耀中, 薛华, 李妍, 等. 非亲缘异基因造血干细胞移植后的血管升压素分泌失调综合征[J]. 中华内科杂志, 2006, 45(10): 853-854. http://dx.chinadoi.cn/10.3760/j.issn:0578-1426.2006.10.023</mixed-citation></ref><ref id="hanspub.40021-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">张翔, 肖毅, 张义成, 耿哲, 周剑峰, 余学锋, 等. 异基因造血干细胞移植后抗利尿激素分泌失调综合征诊治体会[J]. 内科急危重症杂志, 2009, 15(3): 161-163. http://dx.chinadoi.cn/10.3969/j.issn.1007-1024.2009.03.018</mixed-citation></ref><ref id="hanspub.40021-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">肖毅, 张义成, 隗佳, 孙汉英, 刘文励, 周剑峰. 异基因造血干细胞移植后的抗利尿激素分泌失调综合征[C]//中国病理生理学会实验血液学专业委员会. 第12届全国实验血液学会议论文摘要. 中国病理生理学会实验血液学专业委员会: 中国病理生理学会, 2009: 1.</mixed-citation></ref><ref id="hanspub.40021-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Rau, R., Fitzhugh, C.D., Baird, K., Cortez, K.J., Li, L., Fischer, S.H., et al. (2008) Triad of Severe Abdominal Pain, Inappropriate Antidiuretic Hormone Secretion, and Disseminated Varicella-Zoster Virus Infection Preceding Cutaneous Manifestations After Hematopoietic Stem Cell Transplantation: Utility of PCR for Early Recognition and Therapy. The Pediatric Infectious Disease Journal, 27, 265-268. https://doi.org/10.1097/INF.0b013e31815cb239</mixed-citation></ref><ref id="hanspub.40021-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Peri, A., Pirozzi, N., Parenti, G., Festuccia, F. and Menè, P. (2010) Hyponatremia and the Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH). Journal of Endocrinological Investigation, 33, 671-682. 
https://doi.org/10.1007/BF03346668</mixed-citation></ref><ref id="hanspub.40021-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">李银英, 邱磊, 王淑亮. 抗利尿激素分泌失调综合征临床研究现状[J]. 继续医学教育, 2017, 31(6): 74-76.</mixed-citation></ref><ref id="hanspub.40021-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">邵珠林, 徐向进. 结合指南看抗利尿激素分泌异常综合征的最新诊疗进展[J]. 内科急危重症杂志, 2016, 22(4): 247-249.</mixed-citation></ref></ref-list></back></article>